

## Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	<b>C. freundii</b>		<b>C. koseri</b>		<b>E. aerogenes</b>		<b>E. cloacae</b>		<b>E. coli</b>		<b>K. oxytoca</b>	
Amikacin	320	100%	106	100%	225	100%	575	100%	11574	100%	583	100%
Ampicillin	-	-	-	-	-	-	-	-	11574	67%	-	-
Ampicillin/Sul	-	-	106	95%	-	-	-	-	11574	69%	583	55%
Aztreonam	320	89%	106	99%	225	89%	575	86%	11574	95%	583	97%
Cefazolin	-	-	106	84%	-	-	-	-	11033	81%	583	37%
Cefepime	319	99%	106	99%	225	98%	575	96%	11574	95%	583	98%
Cefoxitin	-	-	104	92%	-	-	-	-	11442	94%	579	95%
Ceftazidime	320	87%	106	98%	225	90%	575	86%	11574	95%	583	98%
Ceftriaxone	320	86%	106	98%	225	88%	575	81%	11574	94%	583	97%
Ertapenem	320	98%	106	100%	-	-	575	90%	11574	100%	583	100%
Gentamicin	320	96%	106	98%	225	100%	575	98%	11574	94%	583	99%
Imipenem	320	96%	106	97%	-	-	575	94%	11574	100%	583	99%
Levofloxacin	320	96%	106	97%	225	99%	575	97%	11574	87%	583	99%
Meropenem	318	100%	104	100%	222	100%	572	100%	11442	100%	579	100%
*Nitrofurantoin	282	94%	82	39%	187	20%	381	29%	10851	98%	397	86%
Piperac/Tazo	320	88%	106	98%	225	90%	575	86%	11574	98%	583	96%
Tetracycline	320	87%	106	98%	225	96%	575	91%	11574	82%	583	96%
Tobramycin	320	96%	106	98%	225	100%	575	98%	11574	95%	583	98%
Trim/Sulfa	320	87%	106	98%	225	99%	575	91%	11574	83%	583	97%

\* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Low number of isolates. Results are less statistically valid.

**Reprints and additional information available at:**  
<http://home.nordx.mmc.org/depts/micro/docs/index.htm>

## Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	<b>K. pneumoniae</b>		<b>M. morgani</b>		<b>P. mirabilis</b>		<b>P.aeruginosa</b>		<b>S.marcescens</b>		<b>Ac. baumannii</b>	
Amikacin	2098	100%	137	100%	946	100%	929	99%	260	100%	45	100%
Ampicillin	-	-	-	-	946	77%	-	-	-	-	-	-
Ampicillin/Sul	2098	86%	137	14%	946	83%	-	-	-	-	45	98%
Aztreonam	2098	96%	137	99%	946	99%	929	83%	260	99%	-	-
Cefazolin	2004	88%	137	0%	922	2%	-	-	-	-	-	-
Cefepime	2098	96%	137	100%	946	99%	928	94%	260	98%	45	96%
Cefoxitin	2069	93%	137	65%	938	97%	-	-	-	-	-	-
Ceftazidime	2098	96%	137	94%	946	99%	-	-	260	99%	-	-
Ceftriaxone	2098	96%	137	91%	946	98%	-	-	260	95%	38	71%
Ertapenem	2098	99%	137	98%	946	97%	-	-	259	98%	-	-
Gentamicin	2098	97%	137	93%	946	90%	929	95%	260	99%	45	91%
Imipenem	2098	99%	-	-	-	-	929	83%	260	69%	45	98%
Levofloxacin	2098	99%	137	90%	946	79%	929	83%	260	98%	45	98%
Meropenem	2069	100%	137	99%	-	-	924	90%	258	99%	44	98%
*Nitrofurantoir	1848	38%	-	-	-	-	-	-	-	-	-	-
Piperac/Tazo	2098	95%	137	99%	946	99%	929	92%	260	98%	-	-
Tetracycline	2098	87%	-	-	-	-	-	-	260	0%	45	91%
Tobramycin	2098	96%	137	95%	946	89%	929	98%	260	75%	45	96%
Trim/Sulfa	2098	91%	137	85%	946	79%	-	-	-	-	45	96%

\* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

ESBL incidence rate for 2017 was 5.6%

CRE incidence rate for 2017 was 0.37%

**Reprints and additional information available at:**

<http://home.nordx.mmc.org/depts/micro/docs/Index.htm>

## Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	<b>E. faecalis</b>		<b>E. faecium</b>		<b>S. aureus</b>		<b>S. epidermidis</b>		<b>***MSSA***</b>		<b>***MRSA***</b>	
Ampicillin	1773	100%	150	27%	-	-	-	-	-	-	-	-
Cefazolin	-	-	-	-	4206	73%	1006	46%	3385	99%	1174	1%
Clindamycin	-	-	-	-	3971	77%	535	59%	3200	80%	1113	68%
Daptomycin	1773	98%	150	95%	4207	100%	1006	99%	3385	100%	1175	99%
Doxycycline	1773	41%	150	62%	4207	98%	1006	89%	3385	98%	1175	97%
Erythromycin	453	17%	40	10%	3888	52%	474	35%	3169	67%	1059	11%
Gentamicin	-	-	-	-	4207	99%	891	100%	3385	99%	1175	97%
Levofloxacin	1327	82%	110	16%	4207	81%	1005	64%	3385	93%	1175	47%
Linezolid	1773	100%	150	85%	4207	100%	1006	96%	3385	100%	1175	99%
Moxifloxacin	-	-	-	-	3888	83%	384	100%	3169	93%	1059	51%
*Nitrofurantoin	1328	99%	-	-	341	100%	544	100%	227	100%	129	100%
Oxacillin	-	-	-	-	4207	73%	1004	46%	3385	99%	1175	1%
Penicillin	-	-	-	-	-	-	-	-	-	-	-	-
Quinupr/Dalfo	-	-	150	74%	4207	100%	-	-	3385	100%	1175	100%
#Rifampin	-	-	-	-	4207	100%	1006	99%	3385	100%	1175	100%
Tetracycline	1327	23%	111	16%	4207	94%	1005	82%	3385	94%	1175	94%
Trim/Sulfa	-	-	-	-	4207	96%	-	-	3385	97%	1175	94%
Vancomycin	1773	99%	150	41%	4207	100%	1006	100%	3385	100%	1175	100%
Gent Synergy	1773	82%	150	97%	-	-	-	-	-	-	-	-
Strep Synergy	1773	86%	150	73%	-	-	-	-	-	-	-	-

	<b>H. influenzae</b>		<b>S. pneumoniae</b>			
			Susceptible		Intermediate	
Ampicillin	18	61%	-	-	-	-
Amox/Clav	4	100%	-	-	-	-
Ceftriaxone	14	100%	229	99%	0%	-
Ceftriaxone(Meningitis)	-	-	207	94%	5%	-
Levofloxacin	-	-	176	100%	-	-
Meropenem	-	-	49	98%	2%	-
Penicillin	-	-	229	75%	22%	-
#Rifampin	-	-	48	100%	-	-
Tetracycline	-	-	178	76%	-	-
Trim/Sulfa	4	50%	-	-	-	-
Vancomycin	-	-	48	100%	-	-

\* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

# Rifampin should not be used alone for therapy.

Low number of isolates. Results are less statistically valid

Routine testing of Haemophilus was discontinued in 2016.

H I is tested from sterile sites or upon request.